Market Overview

Express Scripts to Partner With Imprimis Pharmaceuticals to Offer Alternative to Daraprim for $1.00/Pill


Express Scripts (NASDAQ: ESRX) today announced it will partner with Imprimis Pharmaceuticals (NASDAQ: IMMY) to drive access to a low-cost alternative to Daraprim (pyrimethamine), a drug for the treatment of toxoplasmosis that has been recently priced out of reach for people with HIV, pregnant women and others with weakened immune systems.

Imprimis is offering a compounded oral formulation of pyrimethamine and leucovorin (a form of folic acid) for $1 per capsule for people whose pharmacy benefit is managed by Express Scripts.  While the 62-year-old Daraprim was priced $13.50 per pill earlier this year, its owner, Turing Pharmaceuticals, made the decision in September to increase the price to $750 per pill.

The companies expect that prescriptions for the pyrimethamine and leucovorin from Imprimis will be processed starting as early as this week for Express Scripts patients who need the treatment.

"Leveraging our expertise to improve access and affordability to an important medication is the right thing to do for HIV patients and others who could benefit from a combination of pyrimethamine and leucovorin," said Dr. Steve Miller, Senior Vice President and Chief Medical Officer of Express Scripts. "We believe we now have an extremely cost-effective way

See full press release

Posted-In: News Press Releases


Related Articles (ESRX + IMMY)

View Comments and Join the Discussion!

Eisai Announces FDA Accepts NDA for Once-Daily Formulation of Antiobesity Agent Belviq

Walmart Says Mobile Accounts for More than 70% of Traffic to